Table 1.
Characteristics of the development set and validation set.
| Characteristics | Development set (n = 6203) | Validation set (n = 2658) | p-value |
|---|---|---|---|
| Age (years) | 39.1 ± 9.2 | 39.0 ± 9.2 | 0.734 |
| Sex, n (%) | |||
| Male | 3758 (60.6) | 1634 (61.5) | 0.445 |
| Female | 2445 (39.4) | 1024 (38.5) | |
| Height (cm) | 168.7 ± 8.5 | 168.8 ± 8.6 | 0.629 |
| Weight (kg) | 71.56 ± 14.59 | 71.71 ± 14.87 | 0.667 |
| Waist (cm) | 86.89 ± 12.04 | 87.09 ± 12.24 | 0.485 |
| BMI (kg/m2) | 25.01 ± 4.07 | 25.01 ± 4.03 | 0.981 |
| Obesity, n (%) | |||
| No | 3313 (53.4) | 1386 (52.1) | 0.284 |
| Yes | 2890 (46.6) | 1272 (47.9) | |
| Obesity1, n (%) | |||
| No | 3240 (52.2) | 1402 (52.7) | 0.674 |
| Yes | 2963 (47.8) | 1256 (47.3) | |
| FPG (mmol/L) | 5.68 ± 1.53 | 5.75 ± 1.70 | 0.068 |
| ALT (U/L) | 27.90 ± 23.49 | 27.87 ± 22.80 | 0.957 |
| AST (U/L) | 21.79 ± 12.75 | 21.56 ± 11.02 | 0.411 |
| ALB (g/L) | 41.45 ± 15.01 | 41.72 ± 14.63 | 0.437 |
| Cre (μmol/L) | 74.45 ± 14.85 | 74.67 ± 14.27 | 0.526 |
| K (mmol/L) | 4.79 ± 1.36 | 4.80 ± 1.28 | 0.742 |
| Na (mmol/L) | 140.57 ± 7.92 | 140.77 ± 6.50 | 0.252 |
| TC (mmol/L) | 4.73 ± 1.03 | 4.74 ± 0.96 | 0.740 |
| TG (mmol/L) | 1.79 ± 1.32 | 1.79 ± 1.32 | 0.878 |
| TyG | 7.19 ± 0.69 | 7.19 ± 0.71 | 0.630 |
| NAFLD, n (%) | |||
| No | 3916 (63.1) | 1684 (63.4) | 0.859 |
| Yes | 2287 (36.9) | 974 (36.6) | |
Obesity: BMI ≥ 25.0 kg/m2; obesity1: WC > 80 cm for female or WC > 90 cm for male.
BMI body mass index, FPG fasting plasma glucose, ALT alanine aminotransferase, AST aspartate aminotransferase, ALB albumin, Cre creatinine, TC total cholesterol, TG triglycerides, TyG triglycerides and glucose index, NAFLD nonalcoholic fatty liver disease.